Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Quinn›
Products & Services
AddedJun 25, 2026
UpdatedJul 4, 2026
At-home metabolomics health test

Quinn› offers At-home metabolomics health test

Product
Currently Offered

iollo's at-home metabolomics test measures 500+ blood biomarkers to generate personalized health and aging insights.

Loading
Overview
News

iollo offers an at-home metabolomics test that analyzes 500+ blood biomarkers from a finger-stick sample. The service ships a CE-marked collection device to the user's home; the dried sample is returned with a prepaid label and analyzed by tandem mass spectrometry. Machine-learning models compare results against a curated research database to produce reports on biological age, metabolic health, heart health, liver health, immune health, digestive health, and other wellness domains.

Users receive evidence-based recommendations for diet, exercise, supplements, and lifestyle, with the option to retest over time to track biomarker trends. The test is positioned for wellness and prevention rather than clinical diagnosis, and integrates with wearables and other lab results. Pricing is tiered: Essential covers five health areas from $299, Expanded covers ten from $399, and Comprehensive covers nineteen from $459.

At-home metabolomics health test - Classification

Industry
  • Healthcare
Technology
  • AI
  • Bioinformatics
  • Machine Learning
  • Mass Spectrometry
Geographic Exposure
  • Americas
  • Global
Model
  • B2C Subscription
  • Direct
Revenue
  • Subscription
Customer
  • Consumers
Tags
  • Digital Health
  • Health Testing

At-home metabolomics health test - Direct Competitors

  • Viome

    Viome logo

    At-home microbiome and cellular health test

    viome.com

  • InsideTracker

    InsideTracker logo

    InsideTracker Platform

    insidetracker.com

AttributeAt-home metabolomics health testAt-home microbiome and cellular health testInsideTracker Platform
ProviderQuinniollo.com$1M raised · Pre-SeedViomeviome.com$276M raised · Series CInsideTrackerinsidetracker.com$18.2M raised · Series B
Founded202220162009
Sells ToConsumersConsumersConsumers
Pricing ModelSubscription, TransactionalRecurring, TransactionalRecurring
OwnershipVenture CapitalPrivate, Venture CapitalVenture Capital
At-home metabolomics health test

Provider Quinniollo.com$1M raised · Pre-Seed

Founded 2022

Sells To Consumers

Pricing Model Subscription, Transactional

Ownership Venture Capital

At-home microbiome and cellular health test

Provider Viomeviome.com$276M raised · Series C

Founded 2016

Sells To Consumers

Pricing Model Recurring, Transactional

Ownership Private, Venture Capital

InsideTracker Platform

Provider InsideTrackerinsidetracker.com$18.2M raised · Series B

Founded 2009

Sells To Consumers

Pricing Model Recurring

Ownership Venture Capital

Similar Products & Services

  • Superpower Platform logo

    Superpower Platform

    superpower.com